Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
SKIPPirr trial: what clinicians have said so far
Premedication to Reduce Amivantamab Associated Infusion Related Reactions
- NCT05663866 ↗
- Active, not recruiting
- Janssen Research & Development, LLC
- Standard size, estimated: 151–300 verified statements once built
We haven't built an HCP commentary report on SKIPPirr (post-osimertinib EGFRm NSCLC) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on SKIPPirr so far
Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 7 YouTube videos, typically up to 31 once built | |
| 7 posts on X, typically up to 31 once built | |
| 4 podcast episodes, typically up to 18 once built |
The trial
ClinicalTrials.gov- Official title
- Subcutaneous Methotrexate, Oral Dexamethasone or Oral Montelukast for the Prevention of Infusion Related Reaction Associated With Amivantamab, an EGFR-MET Bispecific Antibody, Among Post-osimertinib Treated EGFRm NSCLC; SKIPPirr, a Phase 2 Study
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Dexamethasone; Montelukast; Methotrexate; Amivantamab; Lazertinib
- Arms
- Background Anti-cancer Therapy with Amivantamab Plus Lazertinib · Experimental
- Enrollment
- 68
- Primary outcomes
- Percentage of Participants With Infusion-related Reactions (IRRs) at Cycle 1 Day 1
- Sponsor
- Janssen Research & Development, LLC
- Start
- May 18, 2023
- Primary completion
- Mar 29, 2024
- Results posted
- Yes
- Registry record
- NCT05663866 · updated Nov 3, 2026
Publications
linked from the registry- Spira AI, Paz-Ares L, Han JY, Shih JY, Mascaux C, Roy UB, Zugazagoitia J, Kim YJ, Chiu CH, Kim SW, Nadal E, Gil-Bazo I, Murphy SP, Anderson BG, Xia Y, Wang G, Bauml JM, Chioda M, Simoes J, Mahadevia PJ, Lopes G. Preventing Infusion-Related Reactions With Intravenous Amivantamab-Results From SKIPPirr, a Phase 2 Study: A Brief Report. J Thorac Oncol. 2025 Jun;20(6):809-816. doi: 10.1016/j.jtho.2025.01.018. Epub 2025 Jan 24. PubMed 39864547